Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 9/20 | 0.80 |
| ▸ | PRMT6 | Q96LA8 | 7/20 | 0.80 |
| ▸ | PRMT8 | Q9NR22 | 7/20 | 0.80 |
| ▸ | CARM1 | Q86X55 | 6/20 | 0.80 |
| ▸ | PRMT3 | O60678 | 5/20 | 0.80 |
| ▸ | PPARA | Q07869 | 3/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22854461 | 0.89 | PRMT1 (1.00) | PRMT1PRMT6PRMT8CARM1PRMT3 | |
| SCHEMBL16201332 | 0.79 | PRMT1 (0.51) | PRMT1PRMT6PRMT8CARM1PRMT3 | |
| SCHEMBL16201445 | 0.74 | PRMT1 (0.55) | PRMT1PRMT6PRMT8CARM1PRMT3 | |
| SCHEMBL16201424 | 0.74 | ALDH1A1 (0.47) | PRMT1PRMT6PRMT8CARM1PRMT3 | |
| SCHEMBL16187823 | 0.70 | PRMT1 (0.42) | PRMT1PRMT6PRMT8CARM1PRMT3 | |
| SCHEMBL16187821 | 0.70 | PRMT1 (0.42) | PRMT1PRMT6PRMT8CARM1PRMT3 | |
| SCHEMBL16201446 | 0.70 | PRMT6 (0.42) | PRMT1PRMT6PRMT8CARM1PRMT3 | |
| SCHEMBL26670260 | 0.69 | PRMT3 (0.77) | PRMT1PRMT6PRMT8CARM1PRMT3 | |
| SCHEMBL29076027 | 0.68 | PRMT3 (0.61) | PRMT1PRMT6PRMT8CARM1PRMT3 | |
| SCHEMBL16201159 | 0.68 | PRMT1 (0.65) | PRMT1PRMT6PRMT8CARM1PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857534-B2 | Inhibition of dipeptide repeat proteins | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11857534-B2 | Inhibition of dipeptide repeat proteins | PRMT1, ARGLU1, PRMT3 | PRMT1 1/4885PRMT6 4/4885PRMT8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.